iFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with bacterial infections to receive the right antibiotic, on time, every time.

Currently, these tests take 48-72 hours, but iFAST's tests are 10x faster - giving full quantitative and qualitative results in under 3 hours from a positive blood culture or bacterial isolate.

The technology is cheaper and involve less tedious manual labour than current standard of care, which is based on technology from the mid-1900s! We also offer high throughout (most labs only need one system to accommodate all their requirements).

This is a $4bn market and we will be launching on the UK market at the start of 2026, and in the US and EU the following year.

iFAST Diagnostics

Org chart

Teams

Offices

iFAST Diagnostics

Org chart

Teams

Offices

Related companies